Why every healthcare company should have a microbiome strategy

PharmaBiome’s CEO Tomas de Wouters speaks to PharmaTopTalent about why every healthcare company should have a microbiome strategy:

​Just like the immune system, the microbiome will be part of every serious patient anamnesis and a factor to consider patient stratification and treatment. Some indications will benefit from stand-alone live biotherapeutic product, but even more will improve existing treatment strategies based on microbiome analysis or adjuvant treatment. That is why every Pharma company should understand how the microbiome affects their indications and treatments and what strategy is best for them to address this challenge. The list of big pharma investing and entering the microbiome field is growing quickly.

We see the strength of PharmaBiome in our deep understanding of this new modality that can strongly support pharmaceutical companies in their drug development process.